



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: :  
Gunther HOLZEMANN et al. : Group Art Unit: 1653  
Serial No.: 09/486,062 : Examiner: D. Lukton  
Filed: May 5, 2000 :  
For: CYCLOPEPTIDE DERIVATIVES

RECEIVED

JAN 24 2003

SUPPLEMENTAL REPLY


Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

Further to the Reply filed on December 30, 2002, applicants inform the Patent Office that in the discussion related to Raguse et al., *Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularized head and neck tumor*, applicants erroneously asserted that Cilengitide is a compound according to the present invention. The errors are on page 18, line 12 from the bottom of the page and on page 19, lines 4-5 from the top of the page. Cilengitide is actually a compound in accordance with the invention of U.S. 6,001,961 (commonly assigned). Applicants regret any inconvenience this may have caused the Patent Office. In any event, the discussion of Cilengitide presented in the Reply is still relevant to the issue of enablement for the reasons discussed.

Respectfully submitted,

  
Csaba Henter, (Reg. No. 50,908)  
Brion P. Heaney (Reg. No. 32,542)  
Millen, White, Zelano & Branigan, P.C.  
Arlington Courthouse Plaza I, Suite 1400  
2200 Clarendon Boulevard  
Arlington, VA 22201  
Tel: (703) 812-5331  
Fax: (703) 243-6410  
E-mail: henter@mwzb.com

Filed: January 23, 2003

CH BPH(pdr) K:\MERCK\2075\REPLY SUPPL JAN 2002.DOC